Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer

Publication Date: April 4, 2023

Key Points

Key Points

  • This guideline focuses on patients with advanced, recurrent, or metastatic prostate cancer and noncastrate testosterone levels whose disease is not yet castration-resistant, including those with biochemical recurrence only.
  • The future of noncastrate advanced, recurrent, or metastatic prostate cancer care is predicted to include highly personalized treatment plans based on advanced genetic testing, next generation imaging, and the availability of highly predictive biomarkers.
  • This targeted update is driven by results from recent Phase III clinical trials (ARASENS, PEACE-1, ENZAMET, and ARCHES) and two recent meta-analyses.

Treatment

...reatmen...

...ial Treatment

...tion 1.0(Updated) Docetaxel, abirate...

...N DEPRIVATION THERAPY (ADT) PLUS...

...on 1.1(Updated) For patients with me...

...ion 1.11(New) For patients with de novo m...

Recommendation 1.15(New) For patients with de novo...

....16(New) The recommended regimen for patie...

...1.2(Updated) For patients with low-volume...

...ation 1.3(Updated) For patients with metastatic n...

...PLUS ABIRATERONE...

...ommendation 1.4For patients with high-risk de...

...mmendation 1.5For patients with low-risk de nov...

...mmendation 1.6The recommended regimen fo...

ADT PLUS ENZALU...

Recommendation 1.7(Updated) ADT plus...

...endation 1.8(Updated) The recommend...

...T PLUS APALUTAMI...

...ation 1.9ADT plus apalutamide should also be off...

...dation 1.95(Updated) The recommended regimen for p...


Combination The...

...2.1ADT plus abiraterone and prednisolone sho...

...dation 2.2In resource-constrained settin...


Early Androgen Depri...

...mmendation 3.1Early (immediate) ADT may be offere...


...rmittent Androgen Depri...

Recommendation 4.1Intermittent ther...


...itial Management of Noncastrate Metastatic Prost...